Fibronectin and the critically ill patient: current status.
In summary, deficiency of plasma fibronectin has now been documented in a variety of clinical entities. Persistently low fibronectin may have prognostic value, and in certain patients may provide a clue to occult sepsis and potential organ failure. The clinical benefit of infusion of fibronectin-rich cryoprecipitate or purified human plasma fibronectin has yet to be determined in well-controlled randomized clinical trials. However, if such results become available then infusion of plasma fibronectin may provide a valuable therapeutic modality in the care of the critically-ill patient.
D003422:Critical Care; D005353:Fibronectins / Q000097:blood* / Q000172:deficiency / Q000627:therapeutic use; D006801:Humans; D009102:Multiple Organ Failure / Q000503:physiopathology; D014947:Wounds and Injuries / Q000503:physiopathology
D005353:Fibronectins